Finding out you’re sick is hard enough. Finding out you have a disease shared by less than 1% of the population with no established treatment is something else entirely. Rare disease breaks the ...

Shares of Arcellx, a mid-cap drug developer, headed for their best day on record Monday after Gilead Sciences agreed to buy it in a deal worth $7.8 billion.

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ...

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It’s a great idea to select tomorrow's potential winners and hold on as their stories unfold. If you're ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks. Novartis is shelling out $100 ...